SAN DIEGO, May 17, 2017 /PRNewswire/ -- Astute Medical, Inc., developer of biomarkers for better healthcare, today previewed three abstracts reporting data on the use of the biomarker combination [TIMP-2]x[IGFBP-7] for the prediction of acute kidney injury (AKI) in critically ill patients. The abstracts will be presented during poster sessions at the American Thoracic Society's ATS 2017 conference being held in Washington, D.C. May 19-24.
Researchers in all three cases employed Astute Medical's NephroCheck Test, which detects the two biomarkers and calculates an AKIRisk® Score, to determine patient risk of developing moderate to severe AKI. Several published studies have demonstrated that elevated levels of the urinary biomarkers [TIMP-2]x[IGFBP-7] can signal kidney stress indicative of AKI risk.1,2,3 Early knowledge that a patient is likely to develop AKI may prompt closer patient surveillance and enable physicians to intervene proactively in order to help mitigate or prevent permanent kidney damage or death.4
The highlighted abstracts include a study authored by clinicians from Memorial Sloan Kettering Cancer Center (MSK) analyzing the use of [TIMP-2]x[IGFBP-7] for the assessment of AKI risk in cancer patients hospitalized in the intensive care unit, It has been estimated that cancer patients represent up to 20 percent of hospital intensive care unit admissions, and up to 50 percent of these patients may experience AKI.5,6
Preexisting kidney disease, fluid and electrolyte imbalances, susceptibility to infections and use of nephrotoxic drugs are some of the factors heightening the risk of kidney injury in cancer patients.5 The development of AKI can jeopardize further cancer treatment, affect the delivery of chemotherapy,5 lead to longer length of hospital stay,7 and increase risk of permanent kidney damage4 or other complications that can undermine a patient's quality of life.8
Details of the presentations follow:
|
Session: |
C50-CRITICAL CARE: NON-PULMONARY CRITICAL CARE PROBLEMS |
|
Title: |
Urine Biomarkers TIMP-2 and IGFBP7 Early Predict Acute Kidney Injury in Cancer Patients in the ICU |
|
Date: |
Tuesday, May 23, 2017 |
|
Time: |
9:15 a.m. - 4:15 p.m. |
|
Session: |
C50-CRITICAL CARE: NON-PULMONARY CRITICAL CARE PROBLEMS |
|
Title: |
|
|
Date: |
Tuesday, May 23, 2017 |
|
Time: |
9:15 a.m.- 4:15 p.m. |
|
Funded through the National Institutes of Health | |
|
Session: |
C57-CRITICAL CARE CASE REPORTS: HEMATOLOGY, ONCOLOGY, RHEUMATOLOGY, AND IMMUNOLOGY |
|
Title: |
|
|
Date: |
Tuesday, May 23, 2017 |
|
Time: |
9:15 a.m. - 4:15 p.m. |
|
Funded through the National Institutes of Health |
Important Information About The NephroCheck Test
The NephroCheck Test System is intended to be used in conjunction with clinical evaluation in patients who currently have or have had within the past 24 hours acute cardiovascular and or respiratory compromise and are intensive care unit (ICU) patients as an aid in the risk assessment for moderate or severe AKI within 12 hours of patient assessment. The NephroCheck Test System is intended to be used in patients 21 years of age or older.
Astute Medical's NephroCheck Test received 510(k)-clearance through the FDA's de novo classification. The test is CE-marked and available in Europe.
For additional information visit NephroCheck.com.
About Astute Medical, Inc.
Astute Medical is dedicated to improving outcomes for patients with high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests.
The Company's focus is community- and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.
Astute Medical is a founding corporate partner of 0by25, a human rights initiative aimed at eliminating preventable and treatable deaths from AKI worldwide by 2025.
For additional information, please visit AstuteMedical.com.
Astute Medical®, the AM logo, Astute140®, NephroCheck®, the NephroCheck® logo, and AKIRisk® are registered trademarks of Astute Medical, Inc. in the United States. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see AstuteMedical.com/about/intellectualproperty. PN0646 Rev A 2017/05/12
1 Bihorac A, Chawla L, Shaw A, et al. Validation of Cell-Cycle Arrest Biomarkers for Acute Kidney Injury Using Clinical Adjudication. Am J Respir Crit Care Med. Vol 189, Iss 8, pp 932–939, Apr 15, 2014.
2 Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17:R25.
3 Kellum JA, Chawla LS. Cell-cycle arrest and acute kidney injury: the light and dark sides. Nephrol Dial Transplant. (2015) 0: 1–7doi: 10.1093/ndt/gfv130.
4 Lewington AJ, Cerdá J, Mehta RL. Raising awareness of acute kidney injury: a global perspective of a silent killer. Kidney Int. 2013;84(3):457-467.
5 Hoste EAJ, Bagshaw SM, Bellomo R. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. (2015) 41:1411-1423 DOI 10.1007/s00134-015-3934-7.
6 Lameire et al. Critical Care (2016) 20:209 DOI 10.1186/s13054-016-1382-6.
7 Hobson C, Ozrazgat-Baslanti T, Kuxhausen A, et al. Cost and mortality associated with postoperative acute kidney injury. Ann Surg. 2014;00:1-8.
8 A To Z Health Guide: Acute Kidney Injury. National Kidney Foundation. Available at https://www.kidney.org/atoz/content/AcuteKidneyInjury. [Accessed May 3, 2017).]
SOURCE Astute Medical, Inc.